

9HPT (Dominant hand): Percentage change from Part 1 baseline to each scheduled efficacy visit in Part 2
 Subgroup Analysis: Confirmed Progression of disability
 ITT population

Confirmed Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	158	138	
Mean	25.87	12.84	0.0585
SD	72.621	40.232	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (<=5.5 or >=6) and baseline 9HPT (dominant hand).

9HPT (Dominant hand): Percentage change from Part 1 baseline to each scheduled efficacy visit in Part 2
 Subgroup Analysis: Confirmed Progression of disability
 ITT population

Non Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
P			
Percentage change from Baseline to Week 156			
n	99	133	
Mean	-4.10	-2.63	0.6095
SD	17.661	19.436	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6) and baseline 9HPT (dominant hand).